TY 2699a
Alternative Names: TY-2699aLatest Information Update: 09 Jul 2026
At a glance
- Originator TYK Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Apr 2026 Pharmacodynamics and adverse events data from preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 17 Oct 2025 Efficacy, adverse event and pharmacokinetics data from a phase I trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
- 25 Apr 2025 Adverse events data from a phase I trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)